Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 92%
filed 2026-07-07
Item 3.02
Wheeler Real Estate issued approximately 2.12 million shares of common stock across three tranches in June-July 2026 in exchange for preferred stock held by existing security holders, relying on Section 3(a)(9) exemption. Additionally, the Company issued approximately 739,883 shares cumulatively (275,883 in July 2026 and ~464,000 to date) through redemptions of Series D Cumulative Convertible Preferred Stock, with the conversion price of the 7.00% Subordinated Convertible Notes due 2031 adjusted downward to $0.67 per share, representing a 45% discount and material dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-07
Item 3.02
The filing discloses multiple unregistered sales of equity securities (Class E, I, and Y shares) to accredited investors across May, June, and July 2026, both through a distribution reinvestment plan and private placements, totaling approximately $36.7 million in aggregate purchase prices. These transactions are explicitly exempt under Section 4(a)(2) and Regulation D, and the Item 3.02 classification confirms this is a dilutive equity issuance material to investors assessing the company's capital structure and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-07
Item 1.01
Aethlon Medical entered into a Securities Purchase Agreement on July 6, 2026, to sell 263,000 shares of common stock, 5,633,009 common warrants, 5,370,009 pre-funded warrants, and 225,320 placement agent warrants in a registered public offering priced at $0.71 per unit, raising approximately $4.0 million in gross proceeds. This dilutive equity issuance materially increases the share count and warrant overhang, affecting existing shareholders' ownership percentages and future earnings per share.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-07
Item 3.02
Sculptor Diversified Real Estate Income Trust issued 873,952 unregistered shares across two separate issuances (July 1 and June 12, 2026) for approximately $9.8 million in gross proceeds, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S, including direct sales and reinvestment plan distributions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-07
Item 3.02
Cohen & Steers Income Opportunities REIT issued approximately 1.28 million shares across five share classes on July 1, 2026, raising approximately $15.4 million in aggregate consideration. The shares were sold pursuant to Section 4(a)(2) and Regulation D exemptions from Securities Act registration, which is the hallmark of a private placement. This unregistered equity issuance is dilutive to existing shareholders and material to investor assessment of capital structure and ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-07
Item 3.02
North Haven Net REIT sold 3,044,831 common shares for approximately $63.5 million in an unregistered private offering under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive equity issuance disclosed under Item 3.02, representing a material capital raise that would affect investor assessment of share dilution and the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 8.01
ClearSign Technologies filed a prospectus supplement on July 6, 2026 to recommence an "at the market" offering under which it may sell up to $6,875,000 in common stock shares pursuant to an ATM agreement with H.C. Wainwright & Co. This is a classic dilutive equity issuance under Rule 415, material to investors as it signals potential shareholder dilution and the company's capital-raising needs.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
The Company completed an unregistered private placement of 5,500,000 warrants to the Sponsor and Cantor Fitzgerald at $1.00 per warrant, generating $5.5 million in gross proceeds, with the warrants exercisable into Class A Ordinary Shares.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-07-06
Item 1.01
GridAI Technologies entered into a securities purchase agreement on July 1, 2026, to sell 664,598 shares of common stock, pre-funded warrants, and common stock purchase warrants for approximately $8.5 million in gross proceeds through a private placement relying on Section 4(a)(2) exemption. The transaction includes substantial warrant components (pre-funded warrants exercisable at $0.0001 and common warrants exercisable at $4.47) that significantly increase dilution potential.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-06
EX-99.1
Standard Lithium disclosed the issuance of 3,139,330 common shares under its at-the-market (ATM) equity program during Q2 2026, generating gross proceeds of US$11.3 million. ATM offerings are unregistered equity issuances that dilute existing shareholders and are material capital-raising events, particularly for development-stage companies like Standard Lithium.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-07-06
EX-99.1
The exhibit discloses material equity issuance activity under the Company's at-the-market (ATM) program, which generated approximately US$2.1 million in gross proceeds through the issuance of 3,009,295 Common Shares during Q2 2026 at a weighted average price of US$0.68 per share. The ATM program itself is authorized for up to US$25 million. This represents a dilutive equity issuance that would materially affect a reasonable investor's assessment of share dilution and capital structure. While the exhibit also mentions employee share purchase and director DSU grants, the primary material disclosure is the ATM equity offering activity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 3.02
IGC Pharma issued 4,274,853 shares of common stock to executive officers (CEO Ram Mukunda and CFO Claudia Grimaldi) in a debt-for-equity conversion, canceling $1,154,210 in outstanding obligations. The unregistered private placement under Section 4(a)(2) of the Securities Act represents a material dilutive equity transaction affecting shareholder ownership structure and executive compensation.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 1.01
Scilex entered into a binding term sheet with iHolding Group LLP for a $100 million strategic investment through the private placement of approximately 6.67 million newly issued shares of common stock at $15.00 per share, subject to customary closing conditions including stockholder approval and regulatory approvals.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 8.01
Ouster completed a registered public offering of 3,621,876 shares of common stock at $55.22 per share, raising approximately $191.9 million in net proceeds. This is a material equity issuance disclosed under Item 8.01 that dilutes existing shareholders and represents a significant capital-raising event for the company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-06
Item 3.02
AGENUS issued unregistered warrants to purchase 221,525 shares of common stock, representing a dilutive equity issuance to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
Warburg Pincus Access Fund sold unregistered limited partnership units totaling $11.1 million to third-party investors on June 1, 2026, pursuant to Section 4(a)(2) and Regulation D exemptions, representing a significant capital raise and expansion of the Fund's investor base.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
The filing discloses an unregistered sale of 1,873,541.8118 common shares for $47.3 million in aggregate consideration under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive equity issuance by a REIT in a continuous private offering, exempt from registration. The magnitude ($47.3M) and share count are material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-06
The Company issued 1,465,043 newly created Class B ordinary shares to CEO Shek Kin Pong at US$0.9363 per share (US$1.37M aggregate) in a private subscription agreement closed July 2, 2026. This is a dilutive equity issuance to an insider that increases his voting power to 98.42% of total voting power. The transaction was structured under Regulation S as an offshore private placement, making it an unregistered equity sale characteristic of dilutive issuances under Item 3.02.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-06
The 6-K discloses entry into a Securities Purchase Agreement on July 3, 2026, under which China SXT Pharmaceuticals agreed to issue Class A ordinary shares to an institutional investor for up to $30 million in aggregate, with an initial closing of $3.15 million expected July 6, 2026. The securities were issued in reliance on Regulation D (private placement exemption), not registered under the Securities Act. This is a dilutive equity issuance characteristic of a PIPE or private placement, material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
The filing discloses the third closing of a private placement of Series A Convertible Preferred Stock and Warrants under Section 4(a)(2) and Regulation D Rule 506(c). The Company issued 195 Units (195 Preferred Shares convertible at $0.05 per share and 195 Warrants exercisable at $0.0625 per share) for $195,000 gross proceeds. The Preferred Shares and Warrants are convertible/exercisable into common stock, creating significant dilution to existing shareholders. Item 3.02 explicitly addresses "Unregistered Sales of Equity Securities," confirming this is a dilutive equity issuance requiring registration rights and liquidated damages provisions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-06
Item 8.01
Silvaco is issuing 69,062 shares of common stock to a former Tech-X equityholder as consideration for the Tech-X acquisition—specifically for contingent earnout consideration and post-closing purchase adjustments. This is a dilutive equity issuance without cash proceeds to the company, fitting the definition of dilutive_issuance. While the shares are issued in connection with an M&A transaction (Tech-X Acquisition), the 8-K Item 8.01 disclosure centers on the equity issuance itself rather than the acquisition completion, and the company receives no cash proceeds, making this a capital-dilutive event material to shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-06
The 6-K discloses an amendment to an At Market Sales Agreement increasing the maximum aggregate offering price by $50,000,000 in ordinary shares. This is an unregistered or registered equity issuance program that is dilutive to existing shareholders. The material increase in authorized offering size ($50M additional) represents a significant capital-raising event that would affect investor assessment of dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-06
Item 3.02
The Company issued 5,749,999 Class A ordinary shares to the Sponsor upon conversion of Class B shares, relying on the Section 3(a)(9) exemption from Securities Act registration. This unregistered equity transaction materially increased the outstanding Class A share count from approximately 23 million to 28.7 million shares, affecting share dilution and voting structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 1.01
The filing discloses entry into an Amended and Restated Common Stock Purchase Agreement granting an accredited investor the right to purchase up to $20,000,000 in newly issued shares of common stock, with purchase mechanics tied to VWAP pricing and volume thresholds. This is a classic at-the-market (ATM) or PIPE-like arrangement that creates dilutive equity issuance capacity. The July 2, 2026 amendment further refines the pricing mechanism. Such arrangements are material to equity investors as they represent potential dilution and capital raising activity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 3.02
The company disclosed an unregistered sale of equity securities (Shares) pursuant to the Stock Purchase Agreement, relying on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, representing a material private placement that dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 3.02
The filing discloses conversion of 750,000 shares of Series A Preferred Stock into 750,000,000 shares of common stock by three insiders (Kaltsas, Johnson, and Pumphrey), resulting in a massive increase in common share count from 2.1 million to 752.1 million shares. Although technically exempt from registration under Section 3(a)(9) as an exchange with existing security holders, this represents a highly dilutive issuance of equity that materially affects share ownership and voting power, fitting the dilutive_issuance category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-06
The filing discloses that Boost Run has received over $45 million in gross cash proceeds from the exercise of approximately 4.0 million of its 11.47 million public warrants since the May 8, 2026 business combination closing. This represents a material dilutive issuance of common stock upon warrant exercise, which increases the outstanding share count and raises capital. The company explicitly notes the warrant exercises have "reduced the number of outstanding public warrants and related warrant overhang" and may "simplify its capital structure," indicating this is a significant capital event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
The filing discloses a private placement of 65,591 shares of common stock to the CEO/President/Director at $1.5246 per share for $100,000 in gross proceeds, made in reliance on Section 4(a)(2) and Regulation D exemptions from registration. This is an unregistered sale of equity securities (Item 3.02) that increases the CEO's ownership stake to 10.71% and dilutes existing shareholders. The transaction is material as it involves insider participation and represents a capital raise by an unregistered offering.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Idaho Copper Corporation closed an underwritten public offering of 3,712,000 shares of common stock and accompanying warrants at $4.85 per share, raising approximately $18 million in gross proceeds ($16 million net). The company also granted underwriters a 45-day over-allotment option for an additional 556,800 shares and warrants, with underwriters exercising the warrant portion on July 2, 2026. This is a material registered equity issuance that dilutes existing shareholders and represents a significant capital raise for the company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-06
Item 1.01
The filing discloses two unregistered equity issuances: (1) 750,131,126 shares of common stock plus 3,250,000 shares of Series E Preferred Stock issued to Project Nickel LLC in exchange for settling a $1.22M convertible note, and (2) 150,000,000 shares of common stock issued to David M. Garrity for $50,000 cash. Both transactions are unregistered private placements under Section 3(a)(9) and Section 4(a)(2) of the Securities Act. The massive dilution (900M+ common shares issued) represents a material capital event that would significantly affect investor assessment of ownership and equity value.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 7.01
The Company disclosed entry into a Capital on Demand™ Sales Agreement (ATM Program) with a $25 million aggregate offering price and reported that 2.6 million shares had already been sold, generating $11.6 million in net proceeds. This is a classic at-the-market (ATM) equity offering—an unregistered or registered continuous equity issuance that dilutes existing shareholders. The fact that proceeds were mandatorily used to pay down debt (per the secured term loan facility requirement) underscores financial stress and the dilutive nature of the capital raise.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
The filing discloses an unregistered sale of 97,200.66 common shares for approximately $1,984,000 under Section 4(a)(2) and Regulation D Rule 506, which is a classic private placement. The Item 3.02 designation and the explicit reference to exempt offering mechanics confirm this is a dilutive equity issuance. The sale occurred on July 1, 2026, as part of a continuous private offering.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 8.01
Neutron Holdings completed an initial public offering on July 2, 2026, issuing 6,679,791 shares of Common Stock at $25.00 per share for approximately $167 million in gross proceeds.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
The filing discloses an unregistered sale of 2,931,697 Class S-2 shares for approximately $42.5 million to accredited investors under Section 4(a)(2) and Regulation D. This is a classic dilutive private placement that increases the share count and raises capital, which is material to investors' assessment of ownership dilution and the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
The Company issued 5,500 shares of unregistered Series D Convertible Preferred Stock (stated value $1,000 per share, convertible at $0.25 per share subject to a $0.15 floor) to an accredited investor under Section 4(a)(2) and Rule 506(b) as consideration for the CannEpil® license acquisition, with C/M Capital Partners committing to invest at least $1 million within 60 days and a contingent $1 million sales bonus upon achieving $5 million in cumulative net revenue.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
Blue Owl Real Estate Net Lease Trust sold 18.5 million common shares for approximately $198.3 million in gross proceeds on July 1, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions from Securities Act registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-02
Item 8.01
Eos Energy announced commencement of a rights offering on July 2, 2026, pursuant to a shelf registration statement filed on Form S-3. The offering grants existing shareholders subscription rights to purchase units consisting of common stock and warrants at $5.481 per unit. This is a dilutive equity issuance that will increase the share count and warrant obligations, materially affecting existing shareholders' ownership percentages and the company's capital structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-07-02
EX-99.1
The press release discloses multiple equity issuances and conversions during Q2 2026 that collectively increase shareholder equity by $3.8 million, including: conversion of $2.1 million in related-party loans and convertible debentures into 2,192 Series B Convertible Preferred Shares; conversion of 1,351 Series A Convertible Preferred Shares into ~1.5 million common shares; issuance of 257,638 common shares to settle accrued interest; and exercise of 256,410 warrants. These transactions involve significant dilution to existing shareholders through debt-to-equity conversions and warrant exercises, characteristic of dilutive capital restructuring at a small-cap issuer.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 1.01
Elicio Therapeutics entered into a Securities Purchase Agreement on July 1, 2026, to issue 4,380,313 shares of common stock at $3.43 per share in a registered direct offering, generating approximately $15 million in gross proceeds. The offering is being made pursuant to an effective Form S-3 registration statement, with proceeds intended to fund clinical development and working capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 3.02
The filing discloses an unregistered sale of 47,747 common shares of beneficial interest for $721,943.51 pursuant to subscription agreements and exempt under Section 4(a)(2) and Regulation D. This is a classic private placement of equity securities, which is material to investors as it represents dilution and capital raising activity typical of BDCs.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 8.01
MetaVia Inc. entered into an At The Market (ATM) Offering Agreement on November 6, 2025, and filed a prospectus supplement on July 2, 2026, to offer and sell up to $4,000,000 of common stock shares through Ladenburg Thalmann. This is a classic dilutive equity issuance under Rule 415(a)(4), which creates potential shareholder dilution and is material to investors assessing capital structure and ownership stakes.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 3.02
The operating partnership issued $345 million of exchangeable senior notes to qualified institutional buyers under Rule 144A as an unregistered private placement, with the notes exchangeable into approximately 11.9 million common shares at an initial exchange rate of 28.2466 shares per $1,000 principal.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-02
EX-99.1
This is an at-the-market (ATM) sales agreement dated July 2, 2026, under which NervGen Pharma Corp. authorizes Leerink Partners LLC to sell up to US$50,000,000 of common shares on an ongoing basis. The agreement explicitly permits sales "at market prices" through Nasdaq and other U.S. trading venues (Section 3), with the Company retaining discretion to issue Placement Notices controlling timing and volume. This is a classic dilutive equity issuance arrangement that would materially affect shareholder interests through potential share dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-07-02
Item 1.01
BridgeBio entered into an Investment Agreement on July 1, 2026, under which Sixth Street Partners and HealthCare Royalty (a KKR affiliate) purchased $1 billion in Series A Cumulative Convertible Participating Preferred Stock, convertible into approximately 6.78 million common shares at an initial conversion price of $137.79 per share. This substantial private placement, relying on Section 4(a)(2) exemption, materially dilutes existing shareholders' ownership and voting power while strengthening the company's balance sheet.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 72%
filed 2026-07-02
The 6-K discloses exercise of put options by investors in a September 2025 private placement, requiring the Company to repurchase 1,196,295 Ordinary Shares and 633,931 Pre-Funded Warrants in exchange for 2,114,583 TON tokens and 5,136,459 USDC tokens. While the immediate event is a share repurchase (reducing dilution), the underlying transaction chain originates from the dilutive private placement financing with embedded put rights, which materially affects capital structure and investor rights.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 88%
filed 2026-07-02
Item 1.01
Mitesco entered into a $30 million equity line of credit facility with C/M Capital Partners, L.P., allowing the company to draw capital over 36 months by issuing common stock at a 10% discount to market price, subject to a 4.99% beneficial ownership cap. The company issued a $600,000 Convertible Promissory Note as consideration and agreed to register the shares for resale.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 3.02
Mitesco issued over 4.5 million shares of restricted common stock in unregistered private placements under Regulation D exemptions, including 454,052 shares for Series X Preferred dividends, 3,698,147 shares for Series A Preferred redemptions, 700,000 shares for consulting services, and 400,000 shares as management incentives.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-02
EX-99.1
The exhibit announces completion of an approximately €11.8 million equity raise comprising a €10.65 million equity financing plus €1.1 million from capitalization of bridge loan OID and PIK interest, together with a separate €4 million investment by FOCUS ON NEXT FRONTIER. This represents a material dilutive equity issuance totaling approximately €15.8 million, executed as part of a financial restructuring to strengthen the balance sheet and liquidity position. The involvement of new shareholders (FOCUS) and existing shareholders (Generalitat de Catalunya via IFEM) confirms the issuance of new equity securities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 3.02
PIMCO Asset-Based Lending Co LLC completed an unregistered sale of LLC interests totaling approximately $44.7 million across multiple share classes to third-party investors on June 1, 2026, exempt under Section 4(a)(2) and Regulations D and S. This dilutive issuance materially affects existing shareholders' ownership percentages.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-02
Item 1.01
Veru Inc. entered into an at-the-market (ATM) sales agreement on July 2, 2026, authorizing the issuance and sale of up to $21.8 million of common stock through Oppenheimer & Co. and Canaccord Genuity as sales agents. This is a registered equity offering under Form S-3 that creates potential dilution to existing shareholders and represents a material capital-raising activity typical of dilutive issuances.
View raw filing on EDGAR →